EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Superiority of low‐dose benzbromarone to low‐dose febuxostat in gout patients with renal uric acid underexcretion: comment on the article by Yan et al

Tomoyuki Kawada iD

Arthritis & Rheumatology · 2023

DOI: 10.1002/art.42499 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Arthritis & Rheumatology, 2023. Verfasst von Tomoyuki Kawada. Beteiligte Einrichtung: Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan. Hauptthemen laut MEDLINE: Gout, Hyperuricemia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 3 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GoutHyperuricemiaHumansFebuxostatUric AcidBenzbromaroneGout SuppressantsAllopurinolTreatment Outcome

Substanzen

FebuxostatUric AcidBenzbromaroneGout SuppressantsAllopurinol

Autor:innen und Institutionen

  • Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan.

ORCID-Profile: Tomoyuki Kawada

Zitieren

APA

Kawada, T. (2023). Superiority of low‐dose benzbromarone to low‐dose febuxostat in gout patients with renal uric acid underexcretion: comment on the article by Yan et al. Arthritis & Rheumatology. https://doi.org/10.1002/art.42499

Vancouver

Kawada T. Superiority of low‐dose benzbromarone to low‐dose febuxostat in gout patients with renal uric acid underexcretion: comment on the article by Yan et al. Arthritis & Rheumatology. 2023. doi:10.1002/art.42499

BibTeX
@article{Kawada2023,
  author = {Kawada, Tomoyuki},
  title = {Superiority of low‐dose benzbromarone to low‐dose febuxostat in gout patients with renal uric acid underexcretion: comment on the article by Yan et al},
  journal = {Arthritis & Rheumatology},
  year = {2023},
  doi = {10.1002/art.42499}
}
Kostenlos starten →